Never Run Out Of Buyers To Sell To.

Aclairo’s previous experience as FDA supervisors, reviewers, and drug developers has forged a unique comprehension of the product-specific complexities of pharmaceutical drug development. The Aclairo advantage is our experience-based synergistic approach to providing strategic, scientific review and regulatory services. This has proven to be our greatest asset in focusing and streamlining our clients’ drug development efforts, reducing both time and costs, leading to success. Aclairo is a wholly owned subsidiary of Experimental Pathology Laboratories, Inc. EPL provides a comprehensive range…
Built from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Annual Revenue$10M to $25M
Estimated OwnershipPrivate